

1 **Reliability, validity, and sensitivity of Japanese version of the UCLA Scleroderma**
2 **Clinical Trial Consortium Gastrointestinal Tract Instrument: application to**
3 **efficacy assessment of intravenous immunoglobulin administration.**

4

5 Kazuki M Matsuda^{1*}, MD, PhD, Eiki Sugimoto^{1*}, MD, Yoshiaki Ako¹, MD, Marie

6 Kitamura¹, MD, Mai Miyahara¹, MD, Hirohito Kotani¹, MD, PhD, Yuta Norimatsu¹,

7 MD, PhD, Teruyoshi Hisamoto¹, MD, PhD, Ai Kuzumi¹, MD, PhD, Takemichi

8 Fukasawa,^{1,2} MD, PhD, Shinichi Sato¹, MD, PhD, Ayumi Yoshizaki,^{1,2#} MD, PhD

9 * Contributed equally.

10

11 1. Department of Dermatology, Graduate School of Medicine, The University of

12 Tokyo, Tokyo, Japan

13 2. Department of Clinical Cannabinoid Research, The University of Tokyo Graduate

14 School of Medicine, Tokyo, Japan

15

16 **Key words:** Autoantibody, autoimmune diseases, miscellaneous rheumatic and

17 inflammatory diseases.

18

19 **# Corresponding author**

20 Ayumi Yoshizaki, MD, PhD

21 Department of Dermatology, and Department of Clinical Cannabinoid Research, The

22 University of Tokyo Graduate School of Medicine, Tokyo, Japan, 1138655

23 Phone: +81-3-3815-5411

24 ORCID: 0000-0002-6755-8047

25 E-mail: ayuyoshi@me.com

26

27 **Competing interests**

28 TF and AY belong to the Social Cooperation Program, Department of Clinical

29 Cannabinoid Research, supported by Japan Cosmetic Association and Japan Federation

30 of Medium and Small Enterprise Organizations. The remaining authors declare that the

31 research was conducted in the absence of any commercial or financial relationships that

32 could be construed as a potential conflict of interest.

33

34 **Abstract**

35 *Objective*

36 This study aimed to develop and assess the reliability, validity, and sensitivity
37 of Japanese version of the University of California Los Angeles Scleroderma Clinical
38 Trial Consortium Gastrointestinal Tract (GIT) Instrument 2.0 (the GIT score), as an
39 evaluation tool for GIT symptoms in systemic sclerosis (SSc).

40

41 *Methods*

42 Japanese version of the GIT score was constructed using the forward-backward
43 method. The reliability and validity of this instrument were evaluated in a cohort of 38
44 SSc patients. Correlation analysis was conducted to assess the relationship between the
45 GIT score and existing patient-reported outcome measures. Additionally, the sensitivity
46 of the GIT score was examined by comparing GIT scores before and after intravenous
47 immunoglobulin (IVIG) administration in 10 SSc-myositis overlap patients, as IVIG
48 has recently demonstrated effectiveness in alleviating GIT symptoms of SSc.

49

50 *Results*

51 Japanese version of the GIT score exhibited internal consistency and a
52 significant association with the Frequency Scale for the Symptoms of Gastroesophageal
53 Reflux Disease. Furthermore, the total GIT score, as well as the reflux and
54 distention/bloating subscales, displayed moderate correlations with the EQ-5D
55 pain/discomfort subscale, Short Form-36 body pain subscale, and its physical
56 component summary. Notably, following IVIG treatment, there was a statistically
57 significant reduction in the total GIT score and most of the subscales.

58

59 *Conclusion*

60 We firstly validated Japanese version of the GIT score in Japanese SSc patients
61 in real-world clinical settings. This instrument holds promise for application in future
62 clinical trials involving this patient population.

63

64 **Key messages**

- 65 ● What is already known about this subject?

66 Khanna et al. developed the UCLA Scleroderma Clinical Trial Consortium

67 Gastrointestinal Tract (GIT) Instrument (the GIT score) to assess patient-reported

68 GIT symptoms in individuals with systemic sclerosis (SSc).

69

- 70 ● What does this study add?

71 We have developed and established the reliability, validity, and sensitivity of the

72 Japanese version of the GIT score in cohorts of Japanese individuals with SSc.

73

- 74 ● How might this impact on clinical practice?

75 This tool can effectively evaluate GIT manifestations in Japanese SSc patients in

76 routine clinical settings, and potentially in clinical trial contexts.

77

78 **Introduction**

79 Systemic sclerosis (SSc) is a complex connective tissue disease typified by
80 widespread inflammation, vasculopathy, and severe fibrosis affecting various organs
81 including the skin, lungs, and the gastrointestinal tract (GIT).[1] The fibrotic process
82 particularly compromises the GIT by inducing hypomotility, leading to a spectrum of
83 manifestations throughout both the upper and lower GIT, such as gastroesophageal
84 reflux disease (GERD) and intestinal pseudo-obstruction (IPO). Notably, as many as
85 90% of SSc patients suffer GIT abnormalities, which significantly associates with a
86 marked decline in health-related quality of life (HRQOL),[2] extended duration of
87 hospitalization, and in severe cases, increased mortality rates.[3]

88 Although the current therapeutic modalities for addressing the GIT
89 involvement of SSc have been constrained, the emergence of innovative treatment
90 approaches with disease-modifying potential, including biologics[4][5] and autologous
91 hematopoietic stem cell transplantation,[6] harbors promise for more efficacious
92 outcomes. Furthermore, recent investigations have underscored the advantages of
93 intravenous immunoglobulin (IVIG), one of the conventional agents being tried for SSc
94 management characterized by its low adverse event profile, for mitigating the GIT
95 symptoms of SSc.[7] As such, the development of clinical outcome measures that are

96 robust, valid, and sufficiently sensitive for use in clinical trials is imperative to assess
97 the efficacy of these groundbreaking therapies on the GIT symptoms of SSc.

98 The recent trend towards the integration of solid methodologies for capturing
99 patient perspectives in clinical trials has assumed escalating importance in regulatory
100 decision-making, aiming to enhance the 'patient-centeredness' of drug development
101 processes. Consequently, patient-reported outcome measures (PROMs) have become
102 increasingly pertinent in the context of SSc. Given the substantial heterogeneity and
103 complexity of the clinical manifestations in SSc patients, their evaluation necessitates a
104 multidimensional approach. For instance, certain patients may exhibit severe symptoms
105 related to upper GIT involvement, such as reflux, while others may predominantly
106 present complaints attributed to lower GIT abnormalities, such as distention and
107 bloating. Furthermore, conditions that appear mutually exclusive, such as diarrhea and
108 constipation, may paradoxically coexist at varying times throughout the disease
109 progression. This co-occurrence further complicates the comprehensive communication
110 of the full spectrum of GIT symptoms between patients and clinicians.

111 In an effort to develop a PROM to subjectively and holistically quantify GIT
112 involvement in SSc patients, Khanna et al. conceptualized the SSc-GIT 1.0 in 2007.[8]
113 This tool was initially formulated as a 52-item questionnaire, the content of which was

114 guided by an extensive literature review, expert consensus, and the findings from two
115 focus groups. Subsequently, in 2009, Khanna et al. introduced a more concise and
116 refined version known as the University of California Los Angeles (UCLA)
117 Scleroderma Clinical Trial Consortium (SCTC) GIT 2.0 Instrument (the GIT score),
118 which comprised of 34 items.[9] Evidence suggests that the GIT score exhibits
119 commendable test-retest reliability. Further, both the total and subscale scores were
120 shown to effectively differentiate between patients with mild, moderate, and severe
121 self-rated GIT involvement. Thus, its application in both clinical trials and routine
122 patient care has been strongly endorsed.

123 The GIT score has been adapted and validated in multiple languages, including
124 but not limited to French,[10] Dutch,[11] Italian,[12] Romanian,[13] and Chinese.[14]
125 Although a Japanese translation of the questionnaire has been made available by
126 Khanna et al. online, it has yet to undergo validation within the Japanese population. In
127 light of this, we undertook the reformation of the Japanese version of the GIT score,
128 based on its original counterpart. This newly adapted tool was then implemented in a
129 cohort of Japanese patients with SSc in our clinic, and its reliability and validity were
130 evaluated using statistical methodologies. We also assessed the correlation between the
131 GIT scores and clinical manifestations or autoantibody profiles of SSc patients in Japan.

132 Furthermore, we gauged the sensitivity of Japanese version of the GIT score by
133 comparing scores before and after the administration of IVIG, which demonstrated
134 rapid improvement of GIT symptoms of SSc in a previous study.[7] In this study, our
135 primary objective is to establish this questionnaire as a benchmark tool for evaluating
136 therapeutic efficacy in clinical trials involving the Japanese population.

137 **Materials and Methods**

138 *Translation*

139 We utilized the "forward-backward method"[15] to construct a Japanese
140 adaptation of the GIT score. The process began with independent translations by two
141 translators (KMM and ES), both native speakers of Japanese. They then came together
142 to scrutinize each item, identifying and resolving any potential points of confusion or
143 ambiguity until they reached a consensus. This intermediate version of the instrument
144 was then tested on 10 non-bilingual SSc subjects with no issues arising in relation to
145 clarity or comprehension. Subsequently, this version underwent back-translation by two
146 bilingual translators. The English rendition produced from this process was critically
147 reviewed by 2 native English speakers, who found no need for further modifications
148 **(Supplementary Data 1)**.

149

150 *Patients*

151 We consecutively recruited Japanese patients with SSc visiting our scleroderma
152 center outpatient clinic from November 2022 until April 2023 for assessing the
153 reliability and validity of Japanese version of the GIT score. All the SSc patients
154 fulfilled the classification criteria established by the American College of

155 Rheumatology and European League Against Rheumatism in 2013.[16] We also
156 sequentially enrolled patients with SSc-myositis overlap admitted to our wards from
157 April 2023 until August 2023 for IVIG administration for evaluating sensitivity of
158 Japanese version of the GIT score. This study was approved by The University of
159 Tokyo Ethical Committee (Approval Number 0695). Written informed consent was
160 obtained from all the human subjects.

161

162 *Clinical data acquisition*

163 Clinical data were collected by retrospective review of electric medical records.
164 We gathered basic patient information, symptoms, medications, and laboratory findings
165 from the closest time point from the date of the GIT score evaluation. SSc patients were
166 categorized by LeRoy's classification rule into diffuse cutaneous SSc (dcSSc), limited
167 cutaneous SSc (lcSSc), or overlap syndrome.[17] Skin thickness was
168 semi-quantitatively examined by the modified Rodnan total skin thickness score
169 (mRSS).[18] Interstitial lung disease (ILD), pulmonary hypertension (PH), and
170 scleroderma renal crisis (SRC) were diagnosed as previously described.[19]

171

172 *Autoantibody detection*

173 Autoantibodies in the serum samples were evaluated utilizing autoantibody
174 array assay (A-Cube) as previously described.[20][21] Briefly, a total of 65 antigens of
175 43 autoantibodies associated with SSc, Sjogren syndrome (SjS), primary biliary
176 cholangitis (PBC), myositis, and overlap syndrome, with FLAG-GST-tag on the
177 N-terminus were synthesized *in vitro* with a wheat germ cell-free translation
178 system,[22] from human cDNA library entry clones.[23] The synthesized proteins were
179 captured on array plates under wet conditions by affinity between the GST tags and
180 glutathione (GSH) coated over the glass slides.[24] Then the slides were consequently
181 treated with serum samples diluted in the blocking buffer and fluorescence-labeled
182 anti-human IgG antibody (Ab). After the slides were washed and air-dried, the plates
183 were scanned by a fluorescence imager (**Supplementary Figure A**). The negative
184 control spots were prepared using distilled water instead of mRNA during protein
185 preparation. The positive control spots were prepared using mRNA encoding human
186 IgG for protein synthesis. The autoantibody quantification was performed based on the
187 fluorescent values obtained from reactions of serum with the protein spots. The level of
188 each autoantibody was calculated as below:

$$Index\ value = \frac{F_{autoantigen} - F_{negative\ control}}{F_{positive\ control} - F_{negative\ control}} \times 100$$

$F_{autoantigen}$: Fluorescent intensity of autoantigen spot

$F_{negative\ control}$: Fluorescence intensity of negative control spot

$F_{positive\ control}$: Fluorescence intensity of positive control spot

189 The cut-off value of each autoantigen was determined based on the mean + 3 standard
190 deviation (SD) of healthy controls.

191

192 *Cytokine measurement*

193 The serum levels of cytokines were measured by Luminex Discovery Assay
194 Human Premixed Multi-Analyte Kit (R&D Systems, Minneapolis, MN, USA)
195 according to the manufacturer's protocol. The evaluated cytokines were as follows:
196 tumor necrosis factor-alpha (TNF- α), interleukin 6 (IL-6), interleukin 10 (IL-10),
197 interleukin 27 (IL-27), vascular endothelial growth factor (VEGF), interferon-gamma
198 (IFN- γ), interleukin 31 (IL-31), interleukin 1 alpha (IL-1 α), interleukin 4 (IL-4),
199 interleukin 17 (IL-17), B cell activating factor belonging to the tumor necrosis factor
200 family (BAFF), interleukin 13 (IL-13), interferon alpha (IFN- α), and interleukin 23
201 (IL-23).

202

203 *Patient-reported outcome measures*

204 Patients completed the Japanese version of the GIT score, Medical Outcomes
205 Short Form (SF)-36,[25] the EQ-5D with five levels tool,[26] and the F-scale.[27]
206 UCLA SCTC GIT 2.0 comprises 34 items divided into seven domains: reflux,
207 distention/bloating, diarrhea, fecal soilage, constipation, emotional well-being, and
208 social functioning.[9] Each domain is rated from 0 (indicating better HRQOL) to 3
209 (representing poorer HRQOL), with the exception of the diarrhea and constipation
210 domains, which have a range of 0–2 and 0–2.5, respectively. The overall GIT score is
211 the mean score of six out of the seven domains, excluding constipation, and varies from
212 0 (higher HRQOL) to 3 (lower HRQOL). The original version in English is accessible
213 online at <http://uclascleroderma.researchcore.org/>.

214 The SF-36 is a broad-spectrum measure of health status, comprised of 36 items
215 that evaluate 8 distinct domains.[25] Four scales examine physical health, namely
216 physical functioning (10 items), bodily pain (2 items), role limitations resulting from
217 physical health perceptions (4 items), and overall health perceptions (5 items). An
218 additional four scales are dedicated to mental health, which include mental health (5
219 items), role limitations due to emotional concerns (3 items), vitality (4 items), and social
220 functioning (2 items), alongside a single-item health transition scale. The physical
221 health scales collectively form the Physical Component Summary (PCS), and the

222 mental health scales together make up the Mental Component Summary (MCS). These
223 summarized scores are normalized to the general population in Japan, which is
224 characterized by a mean \pm SD score of 50 ± 10 . [28] A standard 4-week recall period
225 was implemented.

226 The EQ-5D questionnaire with five levels is a generic instrument to quantify
227 HRQOL. [26] The EuroQoL Group developed and tested this tool for the purpose of
228 providing measurable health outcomes. In an initial study with SSc patients, the Italian
229 version of this tool proved to be valid. [12] The EQ-5D is composed of two primary
230 components: the first section, known as the EQ-5D profile, generates a health profile
231 derived from a descriptive system. This system defines health based on five dimensions:
232 'mobility', 'self-care', 'usual activities', 'pain or discomfort', and 'anxiety or depression'.
233 Each dimension offers three response categories indicating no problems, some problems,
234 or extreme problems. The second component of the questionnaire is the EQ-5D Visual
235 Analogue Scale (VAS), which evaluates the overall HRQOL on a scale from 0 (the
236 worst possible health state) to 100 (the best possible health state). For this study, a
237 standard 4-week recall period was employed.

238 F-scale refers to the Frequency Scale for the Symptoms of GERD (FSSG),
239 which is a self-report questionnaire used to assess the frequency and severity of

240 GERD-related symptoms, originally developed in Japan.[27] The FSSG consists of 12
241 items grouped into two subscales: a reflux-related subscale (acid regurgitation and
242 heartburn) and a dysmotility-related subscale (including symptoms like non-cardiac
243 chest pain, a sensation of a lump in the throat, belching, etc.). Each item is rated on a
244 4-point scale (ranging from never = 0, occasionally = 1, sometimes = 2, often = 3), and
245 the scores are added together to provide a measure of the severity of GERD symptoms.

246

247 *Statistical analysis*

248 We analyzed average scores, SDs, ranges, and the percentage of missing data.
249 The floor and ceiling effects of the GIT score were determined by calculating the
250 percentage of participants who scored at the extreme lower (floor) and upper (ceiling)
251 limits. We gauged the internal consistency of the GIT score through Cronbach's
252 alpha.[29] We evaluated the construct convergent validity by examining the relationship
253 among the GIT score, the EQ-5D, and the SF-36 domains, using Spearman's rho to
254 measure correlations. The association between the GIT scores and clinical
255 manifestations or autoantibody profiles was investigated by logistic regression analyses.
256 Data analysis was performed using Stata 15/IC (StataCorp, College Station, TX, USA),
257 GraphPad Prism 9 (GraphPad Software, Boston, MA, USA), R, RStudio, and R

258 packages “dplyr”, “ggplot2”, “hrbrthemes”, “ggcorrplot”, and “ComplexUpset”. We set

259 the threshold for statistical significance at $P < 0.05$.

260

261 **Results**

262 *Study population*

263 We recruited 38 patients with SSc for the assessment of reliability and validity
264 of Japanese SCTC UCLA GIT 2.0 (**Table 1**). A large majority were female (94%) with
265 the mean age of 65 years with SD of 11 years, all of whom were of Japanese ethnicity.
266 The proportion of the patients classified into dcSSc was 21%. None of the subjects
267 within this cohort had been classified as overlap with myositis. Comprehensive
268 autoantibody screening utilizing A-Cube revealed anti-centromere Ab,
269 anti-topoisomerase I Ab, anti-RNA polymerase III Ab, and anti-U1-RNP Ab with the
270 prevalence rate of 45%, 26%, 16%, and 5%, respectively (**Supplementary Figure 1B**
271 **and 1C**).

272

273 *Reliability*

274 The average GIT score was 0.29 (SD 0.33), with 24% reporting no symptoms
275 (total score = 0), 55% reporting mild symptoms (total score = 0.01–0.49), 16%
276 reporting moderate symptoms (total score = 0.50–1.00), and 5% reporting severe
277 symptoms (total score = 1.01–3.00). All multi-item subscales displayed a Cronbach's
278 alpha ranging from 0.67 to 0.92 (**Table 2**). A significant floor effect was evident for the

279 total score and all its subscales, ranging from 24% (total score) to 89% (fecal soilage),
280 while there was no observable ceiling effect.

281

282 *Validity*

283 The reflux subscale and the distention/bloating subscale of the GIT score
284 showed strong and significant correlation with the total score, the reflux subscale, and
285 the dyspepsia subscale of the F-scale (**Table 3**). The total GIT score, the reflux and
286 distention/bloating subscales also demonstrated moderate correlations with the EQ-5D
287 pain/discomfort subscale, the SF-36 BP subscale, and the SF-36 physical component
288 summary. Furthermore, there was a statistically significant, although weak, correlation
289 between selected GIT subscales and certain SF-36 domains and components.

290

291 *Association between clinical features*

292 No statistically significant correlation was observed between the GIT scores
293 and the clinical manifestations of SSc, as indicated in **Supplementary Table 1**.
294 Similarly, there was no significant association between the GIT scores and Ab profiles,
295 as detailed in **Supplementary Table 2**. Meanwhile, a statistically significant correlation
296 was observed between the serum levels of several cytokines and specific GIT subscales,

297 as outlined in **Table 4**. Notably, there was a significant correlation between serum
298 levels of TNF- α or IL-6 and the reflux subscale, as illustrated in **Figure 1A and 1B**.
299 Additionally, a significant correlation was found between serum levels of VEGF and the
300 social functioning or constipation subscales, as depicted in **Figure 1C and 1D**.

301

302 *Sensitivity*

303 We enrolled a cohort of 10 Japanese patients diagnosed with SSc-myositis
304 overlap, with a predominance of 9 female patients (90%). Their average age was 65
305 years, with a SD of 8 years. Among the patients, 6 patients were positive for
306 anti-centromere Ab, 2 patients were positive for anti-U3-RNP Ab positivity, and one
307 patient was positive for anti-RNA polymerase III Ab. Japanese version of the GIT score
308 was administered both before and after IVIG treatment (**Figure 2A**), revealing a
309 reduction in total GIT scores with statistical significance, as well as in a large part of the
310 subscales, except for fecal soilage and constipation (**Figure 2B**).

311 **Discussion**

312 In the present study, Japanese version of the UCLA SCTC GIT 2.0 instrument
313 demonstrated commendable internal consistency and good reliability (**Table 2**),
314 comparable with its original version[9]. Additionally, Japanese version of the GIT score
315 exhibited robust divergent validity demonstrated by significant association with F-scale
316 (**Table 3**), suggesting its usefulness as a tool for evaluating GIT symptoms associated
317 with SSc in real clinical settings. GIT symptoms receive less attention than other
318 symptoms of SSc; GIT manifestations are not evaluated in composite measures of the
319 disease such as the American College of Rheumatology Composite Response Index in
320 Systemic Sclerosis.[30] The absence of significant correlations between GIT score
321 outcomes and other clinical manifestations of SSc affirmed that GIT involvement in
322 SSc stands as an independent factor (**Supplementary Table 1**), warranting separate
323 evaluation.

324 When contrasted with the original study utilizing the English version,[9]
325 several baseline differences in the study population were observed (**Table 1**). The
326 Japanese version assessment was conducted on a smaller patient population (n=38 vs.
327 152); the patients were older (mean age = 65 vs. 51 years); and our evaluation indicated
328 lower mean scores in all the subscales: reflux (0.25 vs. 0.69), distention/bloating (0.70

329 vs. 1.07), fecal soilage (0.13 vs. 0.30), diarrhea (0.49 vs. 0.56), social functioning (0.21
330 vs. 0.26), emotional well-being (0.17 vs. 0.49), constipation (0.36 vs. 0.43), and total
331 GIT score (0.29 vs. 0.66). One explanation might be the higher proportion of patients
332 already treated; most of our patients had already on proton pump inhibitors (89%).
333 Alternatively, one could interpret our study as having enrolled individuals with SSc
334 who had comparatively milder disease manifestations and lesser health impairments.
335 This interpretation finds support in our assessment of HRQOL, revealing a mean SF-36
336 PCS and MCS score of 41.2 and 50.4, respectively, in contrast to the original study
337 where these scores were 36.7 and 47.1, respectively. Moreover, our study featured a
338 smaller proportion of patients with dcSSc (22% vs. 55%), a factor associated with
339 severe gastrointestinal involvement in SSc.[31]

340 An advantage of this study is the multi-dimensional immunophenotyping
341 conducted, which encompassed assessments of serum cytokine levels and autoantibody
342 profiles, aligned with the GIT score outcomes. As a result, we found that the serum
343 levels of TNF- α , IL-6, and VEGF were significantly correlated with the specific
344 subclass of the GIT score (**Figure 1**). Elevation of serum levels compared to healthy
345 controls and correlation with clinical manifestations of SSc have been reported
346 regarding TNF- α ,[32] IL-6,[33] and VEGF.[34] The involvement of IL-6 in the

347 pathogenesis of SSc has been strongly suggested by a substantial body of experimental
348 evidence.[35] This is further supported by the approval of tocilizumab, an anti-IL-6
349 receptor monoclonal antibody, for the treatment of SSc-ILD by the United States Food
350 and Drug Administration.[36] Meanwhile, the therapeutic effectiveness of TNF- α
351 inhibitors in treating SSc has not yet been conclusively demonstrated through
352 randomized placebo-controlled trials, despite some promising findings from smaller
353 observational studies.[37] It's worth noting that experimental studies involving biopsies
354 of patients with GERD have revealed that cultured esophageal epithelial cells,
355 fibroblasts, and muscle cells primarily produce IL-6, rather than TNF- α .[38] This
356 finding opens the possibility of exploring the response of GERD symptoms in SSc
357 patients to anti-IL-6 therapies, assessed using the GIT score, as a compelling avenue for
358 future research investigations.

359 The primary highlight of this study lies in its ability to demonstrate the
360 sensitivity of the GIT score through the improvement observed in the GIT score before
361 and after IVIG administration (**Figure 2**). In a prior publication, we presented evidence
362 of rapid alleviation of subjective symptoms and imaging findings of SSc-related GIT
363 symptoms such as intestinal pseudo-obstruction, and moreover, weight recovery and
364 weaning from total parenteral nutrition following regular monthly IVIG treatments in

365 patients with SSc-myositis overlap.[7] Our current study reaffirmed the immediate
366 effectiveness of IVIG, as reflected in the improvement of the GIT score. These finding
367 underscores the utility of the GIT score as a tool for evaluating the effectiveness of
368 IVIG in Japanese SSc patients within real-world clinical settings and, prospectively, in
369 forthcoming clinical trials.

370 Our study has several limitations. Initially, it is important to note that the
371 sample size in our study was relatively modest. This limitation could potentially explain
372 our inability to detect any associations between autoantibody profiles and the GIT
373 scores (**Supplementary Table 2**), even though certain autoantibodies, such as
374 anti-U3-RNP Ab,[39] which are recognized for their association with GI involvement in
375 SSc. Furthermore, it is worth acknowledging that our evaluation of GIT scores before
376 and after IVIG administration followed a retrospective design. Consequently, the
377 potential for biases cannot be entirely ruled out, although we made efforts to minimize
378 them by sequentially enrolling cases. Additionally, it posed challenges to definitively
379 differentiate the impact of SSc from myositis on GIT symptoms, as our assessment was
380 limited to patients with SSc-myositis overlap. To comprehensively address the efficacy
381 and safety of IVIG in managing SSc-related GIT symptoms, future studies should aim

382 for a more rigorous investigation, ideally in a prospective, multicenter, randomized, and

383 placebo-controlled setup.

384

385 **Contributor-ship**

386 Conceptualization: KMM, AY

387 Methodology: KMM

388 Investigation: KMM, ES

389 Clinical data acquisition: KMM, YA, MK, MM, YN, HK, TH, AK, TF

390 Project administration: KMM

391 Supervision: AY, SS

392 Writing – original draft: KMM

393 Writing – review & editing: AY, SS

394

395 **Acknowledgements**

396 We honor and appreciate Prof. Dinesh Khanna for developing and providing us

397 with the original version of the UCLA SCTC GIT 2.0. We thank Ms. Maiko Enomoto

398 and her colleagues for technical assistance and secretary work. We express our gratitude

399 to Ms. Teruko Tani and Ms. Mayumi Odagaki for their assistance in collecting clinical

400 information.

401

402 **Ethical approval information**

403 This study was approved by The University of Tokyo Ethical Committee

404 (Approval number 0695).

405

406 **Data sharing statement**

407 The data analyzed during the current study are available from the

408 corresponding author on reasonable request.

409

410 **References**

- 411 [1] Y. Allanore *et al.*, “Systemic sclerosis,” *Nat. Rev. Dis. Prim.*, vol. 1, pp. 1–21,
412 2015, doi: 10.1038/nrdp.2015.2.
- 413 [2] M. A. Omair and P. Lee, “Effect of gastrointestinal manifestations on quality of
414 life in 87 consecutive patients with systemic sclerosis,” *J. Rheumatol.*, vol. 39, no.
415 5, pp. 992–996, 2012.
- 416 [3] A. Valenzuela *et al.*, “Intestinal pseudo-obstruction in patients with systemic
417 sclerosis: an analysis of the Nationwide Inpatient Sample,” *Rheumatology*
418 (*Oxford*), vol. 55, no. 4, pp. 654–658, 2016.
- 419 [4] S. Ebata *et al.*, “Safety and efficacy of rituximab in systemic sclerosis
420 (DESIREs): a double-blind, investigator-initiated, randomised,
421 placebo-controlled trial,” *Lancet Rheumatol.*, vol. 3, no. 7, pp. e489–e497, 2021.
- 422 [5] S. S. Takemichi Fukasawa, Ayumi Yoshizaki, Satoshi Ebata, Maiko Fukayama,
423 Ai Kuzumi, Yuta Norimatsu, Kazuki M Matsuda, Hirohito Kotani, Hayakazu
424 Sumida, Asako Yoshizaki-Ogawa, Hisashi Kagebayashi, “Interleukin-17
425 pathway inhibition with brodalumab in early systemic sclerosis: analysis of a
426 single-arm, open-label, phase 1 trial,” *J. Am. Acad. Dermatology*, vol. 23, pp.
427 516–9, 2023.

- 428 [6] U. A. Walker, L. A. Saketkoo, and O. Distler, “Haematopoietic stem cell
429 transplantation in systemic sclerosis,” *RMD Open*, vol. 4, no. 1, p. e000533, Jun.
430 2018, doi: 10.1136/rmdopen-2017-000533.
- 431 [7] K. M. Matsuda *et al.*, “Rapid improvement of systemic sclerosis-associated
432 intestinal pseudo-obstruction with intravenous immunoglobulin administration,”
433 *Rheumatology*, no. January, pp. 1–7, 2023.
- 434 [8] D. Khanna *et al.*, “Development of a preliminary scleroderma gastrointestinal
435 tract 1.0 quality of life instrument,” *Arthritis Rheum.*, vol. 57, no. 7, pp.
436 1280–1286, Oct. 2007.
- 437 [9] D. Khanna *et al.*, “Reliability and validity of the university of california, los
438 angeles scleroderma clinical trial consortium gastrointestinal tract instrument,”
439 *Arthritis Care Res.*, vol. 61, no. 9, pp. 1257–1263, 2009.
- 440 [10] S. Bae *et al.*, “Development and validation of French version of the UCLA
441 Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument,” *Clin*
442 *Exp Rheumatol*, vol. 29, pp. S15–S21, 2011.
- 443 [11] J. Meijs, D. Pors, T. P. M. V. Vlieland, T. W. J. Huizinga, A. A. Schouffoer, and
444 D. Pors, “Translation, cross-cultural adaptation, and validation of the UCLA

- 445 Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument (SCTC
446 GIT) 2.0 into Dutch,” *Clin Exp Rheumatol*, vol. 32, pp. S41–S52, 2014.
- 447 [12] R. Gualtierotti *et al.*, “Reliability and validity of the Italian version of the UCLA
448 Scleroderma Clinical Trial Consortium Gastrointestinal Tract Instrument in
449 patients with systemic sclerosis,” *Clin. Exp. Rheumatol.*, vol. 33, pp. 55–60,
450 2015.
- 451 [13] M. Gorga, C. Mihai, A. M. Soare, R. Dobrotă, A. M. Gherghe, and V. Stoica,
452 “Romanian version of the UCLA Scleroderma Clinical Trial Consortium
453 Gastrointestinal Tract Instrument,” *Clin. Exp. Rheumatol.*, vol. 33, no. 14, pp.
454 61–67, 2015.
- 455 [14] A. H. L. Low *et al.*, “Validation of the UCLA Scleroderma Clinical Trial
456 Consortium Gastrointestinal Tract Instrument 2.0 in English- and
457 Chinese-speaking patients in a multi-ethnic Singapore systemic sclerosis cohort,”
458 *Clin. Rheumatol.*, vol. 36, no. 7, pp. 1643–1648, 2017.
- 459 [15] D. E. Beaton, C. Bombardier, F. Guillemin, and M. B. Ferraz, “Guidelines for the
460 process of cross-cultural adaptation of self-report measures.,” *Spine (Phila. Pa.*
461 *1976)*., vol. 25, no. 24, pp. 3186–3191, Dec. 2000.

- 462 [16] F. Van Den Hoogen *et al.*, “2013 classification criteria for systemic sclerosis: An
463 american college of rheumatology/European league against rheumatism
464 collaborative initiative,” *Arthritis Rheum.*, vol. 72, no. 11, pp. 1747–55, 2013.
- 465 [17] W. F. LeRoy EC, Black C, Fleischmajer R, Jablonska S, Krieg T, Medsger TA Jr,
466 Rowell N, “Scleroderma (systemic sclerosis): classification, subsets and
467 pathogenesis.,” *J Rheumatol.*, vol. 15, no. 2, pp. 202–5, 1988.
- 468 [18] P. J. Clements, P. A. Lachenbruch, S. C. Ng, M. Simmons, M. Sterz, and D. E.
469 Furst, “Skin score: A semiquantitative measure of cutaneous involvement that
470 improves prediction of prognosis in systemic sclerosis,” *Arthritis Rheum.*, vol. 33,
471 no. 8, pp. 1256–63, 1990.
- 472 [19] K. M. Matsuda *et al.*, “Skin thickness score as a surrogate marker of organ
473 involvements in systemic sclerosis: a retrospective observational study.,”
474 *Arthritis Res. Ther.*, vol. 21, p. 129, 2019.
- 475 [20] K. M. Matsuda *et al.*, “Autoantibody Landscape Revealed by Wet Protein
476 Array□: Sum of Autoantibody Levels Re flects Disease Status,” *Front.*
477 *Immunol.*, vol. 13, pp. 1–14, 2022.

- 478 [21] A. Kuzumi *et al.*, “Comprehensive autoantibody profiling in systemic
479 autoimmunity by a highly-sensitive multiplex protein array,” *Front. Immunol.*,
480 vol. 14, 2023.
- 481 [22] T. Sawasaki, T. Ogasawara, R. Morishita, and Y. Endo, “A cell-free protein
482 synthesis system for high-throughput proteomics,” *Proc. Natl. Acad. Sci. U. S. A.*,
483 vol. 99, no. 23, pp. 14652–14657, 2002.
- 484 [23] N. Goshima *et al.*, “Human protein factory for converting the transcriptome into
485 an in vitro-expressed proteome,” *Nat. Methods*, vol. 5, no. 12, pp. 1011–1017,
486 2008.
- 487 [24] E. Fukuda *et al.*, “Identification and characterization of the antigen recognized by
488 the germ cell mAb TRA98 using a human comprehensive wet protein array,”
489 *Genes to Cells*, vol. 26, no. 3, pp. 180–189, 2021.
- 490 [25] S. Fukuhara, S. Bito, J. Green, A. Hsiao, and K. Kurokawa, “Translation,
491 Adaptation, and Validation of the SF-36 Health Survey for Use in Japan,” *J. Clin.*
492 *Epidemiol.*, vol. 51, no. 11, pp. 1037–1044, Nov. 1998.
- 493 [26] K. S. Shunya Ikeda, Takeru Shiroyiwa, Ataru Igarashi, Shinichi Noto, Takashi
494 FUKUDA, Shinya Saito, “Developing a Japanese version of the EQ-5D-5L value
495 set,” *J. Natl. Inst. Public Heal.*, vol. 64, no. 1, pp. 47–55, 2015.

- 496 [27] M. Kusano *et al.*, “Development and evaluation of FSSG: frequency scale for the
497 symptoms of GERD,” *J. Gastroenterol.*, vol. 39, no. 9, pp. 888–891, 2004.
- 498 [28] S. Fukuhara, J. E. J. Ware, M. Kosinski, S. Wada, and B. Gandek, “Psychometric
499 and clinical tests of validity of the Japanese SF-36 Health Survey.,” *J. Clin.*
500 *Epidemiol.*, vol. 51, no. 11, pp. 1045–1053, Nov. 1998.
- 501 [29] J. M. Bland and D. G. Altman, “Cronbach’s alpha.,” *BMJ*, vol. 314, no. 7080, p.
502 572, Feb. 1997.
- 503 [30] D. Khanna *et al.*, “The American College of Rheumatology Provisional
504 Composite Response Index for Clinical Trials in Early Diffuse Cutaneous
505 Systemic Sclerosis,” *Arthritis Care Res.*, vol. 68, no. 2, pp. 167–78, 2016.
- 506 [31] E. Dein, P. Kuo, Y. S. Hong, L. K. Hummers, C. A. Mecoili, and Z. H. McMahan,
507 “Evaluation of risk factors for pseudo-obstruction in systemic sclerosis,” *Semin.*
508 *Arthritis Rheum.*, vol. 49, no. 3, pp. 405–410, 2020.
- 509 [32] M. Hasegawa, M. Fujimoto, K. Kikuchi, and K. Takehara, “Elevated serum
510 tumor necrosis factor-alpha levels in patients with systemic sclerosis: association
511 with pulmonary fibrosis.,” *J. Rheumatol.*, vol. 24, no. 4, pp. 663–665, Apr. 1997.
- 512 [33] M. Hasegawa, S. Sato, M. Fujimoto, H. Ihn, K. Kikuchi, and K. Takehara,
513 “Serum levels of interleukin 6 (IL-6), oncostatin M, soluble IL-6 receptor, and

- 514 soluble gp130 in patients with systemic sclerosis.,” *J. Rheumatol.*, vol. 25, no. 2,
515 pp. 308–313, Feb. 1998.
- 516 [34] J.-J. Choi *et al.*, “Elevated vascular endothelial growth factor in systemic
517 sclerosis.,” *J. Rheumatol.*, vol. 30, no. 7, pp. 1529 LP – 1533, Jul. 2003.
- 518 [35] Y. Kawaguchi, “Contribution of Interleukin-6 to the Pathogenesis of Systemic
519 Sclerosis,” *J. Scleroderma Relat. Disord.*, vol. 2, no. 2_suppl, pp. S6–S12, Jan.
520 2017.
- 521 [36] D. Khanna *et al.*, “Safety and efficacy of subcutaneous tocilizumab in adults with
522 systemic sclerosis (faSScinate): a phase 2, randomised, controlled trial,” *Lancet*,
523 vol. 387, pp. 2630–2640, 2016.
- 524 [37] G. Murdaca, F. Spanò, M. Contatore, A. Guastalla, and F. Puppo, “Potential use
525 of TNF- α inhibitors in systemic sclerosis.,” *Immunotherapy*, vol. 6, no. 3, pp.
526 283–289, 2014, doi: 10.2217/imt.13.173.
- 527 [38] F. Rieder *et al.*, “Gastroesophageal Reflux Disease–Associated Esophagitis
528 Induces Endogenous Cytokine Production Leading to Motor Abnormalities,”
529 *Gastroenterology*, vol. 132, no. 1, pp. 154–165, 2007.
- 530 [39] E. Nishimagi, A. Tochimoto, Y. Kawaguchi, T. Satoh, and M. Kuwana,
531 “Characteristics of Patients with Early Systemic Sclerosis and Severe

532 Gastrointestinal Tract Involvement,” *J. Rheumatol.*, vol. 34, no. 10, pp.

533 2050–2055, 2007.

534

535

536 **Figure legends**

537 **Figure 1. Correlation between serum cytokine levels and Japanese UCLA SCTC**

538 **GIT 2.0 scores.** Scatter plots of TNF- α vs. reflux subscale (**A**), IL-6 vs. reflux subscale

539 (**B**), VEGF vs. social functioning subscale (**C**), and VEGF vs. constipation subscale (**D**).

540 r: Spearman's rho. * $P < 0.05$. The red line and the green area represent the regression

541 line and its 95% confidence interval.

542

543 **Figure 2. Sensitivity of UCLA SCTC GIT 2.0 in relation to IVIG administration.**

544 (A) Schematic figures of the study design. Japanese version of the GIT score was

545 analyzed on day 1 and day 7. IVIG 2 g/kg was administered over 5 days (day 2-6). (B)

546 The total GIT score and subscales before and after IVIG administration. *P* values were

547 calculated by Wilcoxon signed-rank test. * $P < 0.05$.

548

549 **Supplementary Figure 1.** Autoantibody profiling. **(A)** Schematic figures of A-Cube.
550 Synthesized antigens were displayed on glass slides in an array format. The arrays were
551 treated with patients' serum, followed by application of fluorescence-labeled secondary
552 antibodies specific to human IgG. The serum levels of each autoantibody were
553 determined through analysis of the resulting fluorescence image. GSH: glutathione. **(B)**
554 Correlational heatmap between each autoantibody. r : Spearman's rho. The size of each
555 circle represents the P value. **(C)** The UpSet plot of autoantibodies.
556

557 **Table 1. Background of the patients for reliability and validity assessment.**

| | |
|-----------------------------------|----------|
| Number of patients | 38 |
| Basic demographics | |
| Age, years | 65±11 |
| Female, n (%) | 36 (95%) |
| Disease duration, years | 9±7 |
| BMI | 20±3 |
| Autoantibodies | |
| Anti-topoisomerase I Ab, n (%) | 10 (26%) |
| Anti-centromere Ab, n (%) | 17 (45%) |
| Anti-RNA polymerase III Ab, n (%) | 6 (16%) |
| Anti-U1-RNP Ab, n (%) | 2 (5%) |
| Type of SSc | |
| lcSSc, n (%) | 28 (74%) |
| dcSSc, n (%) | 8 (21%) |

Overlap with SLE, n (%) 2 (5%)

Overlap with PM/DM, n (%) 0 (0%)

Skin manifestations

Diffuse skin sclerosis, n (%) 10 (26%)

mRSS 13±9

Puffy fingers, n (%) 30 (79%)

Telangiectasia, n (%) 20 (53%)

Calcinosis, n (%) 5 (13%)

Peripheral angiopathy

Normal, n (%) 4 (11%)

Raynaud's phenomenon, n (%) 16 (42%)

Pitting scars, n (%) 11 (29%)

Digital ulcers, n (%) 6 (16%)

Gangrenes, n (%) 1 (3%)

N of ulcerated fingers, n (%) 3±4

Organ involvements

| | |
|------------|----------|
| ILD, n (%) | 16 (42%) |
| PH, n (%) | 4 (11%) |
| SRC, n (%) | 1 (3%) |

Medications

| | |
|--|----------|
| PPI, n (%) | 34 (89%) |
| Calcium channel blockers, n (%) | 7 (18%) |
| Corticosteroids , n (%) | 13 (34%) |
| Endothelin receptor antagonists, n (%) | 18 (47%) |

Objective clinical outcome measures

| | |
|---------------------|---------|
| %FVC | 97±19 |
| %DLco | 89±18 |
| KL-6 | 245±75 |
| SP-D | 72±36 |
| Serum albumin, g/dL | 4.4±1.0 |

Serum TG, mg/dL 134±55

PROMs

F-scale

Reflux score 7±6

Dyspeptic score 6±5

Total score 13±11

SF-36

PF 77±22

RP 71±28

BP 59±24

GH 46±15

VT 55±20

SF 77±27

RE 79±26

MH 70±18

| | |
|--------------------|-----------|
| PCS | 42±13 |
| MCS | 50±8 |
| EQ-5D | |
| Mobility | 0.39±0.72 |
| Self-care | 0.21±0.47 |
| Usual activities | 0.66±0.88 |
| Pain/Discomfort | 0.87±0.91 |
| Anxiety/Depression | 0.42±0.76 |
| VAS | 66±18 |

558 Unless noted otherwise, values are means ± SD.

559

560 **Table 2. Descriptive statistics and internal consistency reliability of the Japanese**

561 **UCLA SCTC GIT 2.0.**

| Subclass | Mean (SD) | Min | Max | Cronbach's α | Floor effect (%) | Ceiling effect (%) |
|-------------------------|----------------------|------------|------------|---|---------------------------------|-----------------------------------|
| Reflux | 0.25 (0.37) | 0 | 1.625 | 0.77 | 17 (45%) | 0 (0%) |
| Distention/bloating | 0.70 (0.67) | 0 | 2.25 | 0.76 | 12 (32%) | 0 (0%) |
| Fecal soilage | 0.13 (0.41) | 0 | 2 | NA | 34 (89%) | 0 (0%) |
| Diarrhea | 0.49 (0.68) | 0 | 3 | 0.67 | 20 (53%) | 1 (%) |
| Social functioning | 0.21 (0.37) | 0 | 1.5 | 0.76 | 24 (63%) | 0 (0%) |
| Emotional well-being | 0.17 (0.33) | 0 | 1.67 | 0.78 | 21 (55%) | 0 (0%) |
| Constipation | 0.36 (0.53) | 0 | 1.75 | 0.73 | 19 (50%) | 0 (0%) |
| Total GIT score | 0.29 (0.33) | 0 | 1.27 | 0.92 | 9 (24%) | 0 (0%) |

562 NA: not applicable.

563

Table 3. Spearman’s correlation coefficients among PROMs

| | Reflux | Distention/ Bloating | Fecal soilage | Diarrhea | Social functioning | Emotional well being | Constipation | Total |
|------------------|-----------------|-------------------------|------------------|----------------|-----------------------|-------------------------|--------------|-----------------|
| F-scale | | | | | | | | |
| Reflux | 0.79**** | 0.71**** | 0.10 | 0.49** | 0.43** | 0.47** | 0.21 | 0.73**** |
| Dyspepsia | 0.58*** | 0.77**** | 0.18 | 0.59*** | 0.48** | 0.45** | 0.34* | 0.74**** |
| Total | 0.72**** | 0.77**** | 0.15 | 0.56*** | 0.47** | 0.48** | 0.29 | 0.77**** |
| EQ-5D | | | | | | | | |
| Mobility | 0.27 | 0.10 | -0.05 | -0.14 | 0.05 | -0.07 | -0.02 | 0.08 |
| Self-care | 0.24 | 0.21 | -0.16 | 0.04 | -0.07 | 0.02 | 0.11 | 0.16 |
| Usual activities | 0.44** | 0.28 | -0.03 | 0.10 | 0.09 | 0.12 | 0.20 | 0.27 |

| | | | | | | | | |
|--------------------|----------------|----------------|-------|-------|---------------|---------------|--------------|----------------|
| Pain/discomfort | 0.38* | 0.47** | 0.03 | 0.08 | 0.30 | 0.23 | 0.33* | 0.40* |
| Anxiety/depression | 0.08 | 0.13 | -0.02 | 0.09 | 0.03 | 0.13 | 0.12 | 0.12 |
| VAS | -0.18 | -0.19 | 0.03 | 0.03 | -0.06 | -0.13 | -0.11 | -0.16 |
| SD-36 | | | | | | | | |
| PF | -0.39* | -0.12 | 0.10 | 0.14 | -0.06 | 0.09 | 0.08 | -0.09 |
| RP | -0.36* | -0.18 | -0.02 | -0.13 | -0.21 | 0.05 | -0.18 | -0.20 |
| BP | -0.49** | -0.49** | -0.09 | -0.25 | -0.33* | -0.40* | -0.25 | -0.51** |
| GH | -0.21 | -0.36* | -0.13 | -0.10 | -0.08 | -0.37* | -0.08 | -0.33* |
| VT | -0.34* | -0.23 | 0.04 | -0.04 | -0.09 | -0.03 | 0.03 | -0.20 |
| SF | -0.27 | -0.12 | 0.18 | -0.14 | 0.08 | -0.07 | 0.12 | -0.16 |
| RE | -0.32 | -0.28 | 0.01 | -0.04 | 0.00 | -0.04 | 0.13 | -0.21 |

| | | | | | | | | |
|-----|----------------|---------------|-------|-------|-------|-------|-------|---------------|
| MH | -0.01 | 0.03 | 0.12 | -0.03 | 0.23 | 0.01 | 0.20 | 0.04 |
| PCS | -0.51** | -0.34* | -0.12 | -0.12 | -0.23 | -0.09 | -0.13 | -0.33* |
| MCS | -0.03 | -0.10 | 0.07 | -0.07 | 0.08 | -0.16 | 0.12 | -0.10 |


Boldface letters mean statistically significant. * $P < 0.05$, ** $P < 0.01$, *** $P < 0.001$, **** $P < 0.0001$.

Table 4. Association between serum cytokine levels and the UCLA SCTC GIT scores.


| Cytokine | Serum level, pg/mL | Spearman's rho | | | | | | | Total GIT score |
|---------------|--------------------|----------------|----------------------|---------------|----------|--------------------|----------------------|--------------|-----------------|
| | | Reflux | Distention /Bloating | Fecal soilage | Diarrhea | Social functioning | Emotional well-being | Constipation | |
| TNF- α | 8.2 \pm 3.1 | 0.41* | -0.05 | -0.26 | -0.12 | -0.10 | -0.11 | -0.11 | -0.02 |
| IL-6 | 6.5 \pm 7.2 | 0.41* | -0.06 | -0.35 | -0.08 | -0.23 | -0.12 | 0.12 | -0.03 |
| IL-10 | 4.2 \pm 2.2 | -0.09 | -0.23 | -0.18 | -0.31 | -0.17 | -0.21 | -0.18 | -0.27 |
| IL-27 | 196 \pm 68 | -0.34 | -0.13 | 0.04 | -0.22 | 0.18 | 0.07 | 0.06 | -0.09 |
| VEGF | 94 \pm 35 | 0.01 | -0.01 | -0.02 | 0.09 | 0.41* | 0.12 | 0.48* | 0.11 |
| IFN- γ | 36 \pm 19 | 0.12 | -0.18 | -0.15 | -0.18 | -0.26 | -0.17 | -0.24 | -0.19 |

| | | | | | | | | | |
|---------------|---------|-------|-------|-------|-------|-------|-------|-------|-------|
| IL-31 | 62±31 | -0.15 | -0.06 | 0.11 | 0.06 | -0.26 | 0.00 | 0.00 | -0.09 |
| IL-1 α | 9.4±4.1 | 0.06 | -0.29 | -0.26 | -0.21 | -0.31 | -0.16 | -0.20 | -0.26 |
| IL-4 | 102±30 | 0.06 | -0.28 | -0.19 | -0.18 | -0.30 | -0.17 | 0.18 | -0.24 |
| IL-17 | 4.9±1.3 | -0.33 | -0.38 | -0.14 | -0.18 | -0.14 | -0.25 | 0.00 | -0.38 |
| BAFF | 920±269 | 0.14 | -0.17 | -0.13 | -0.13 | -0.22 | -0.10 | -0.18 | -0.15 |
| IL-13 | 354±106 | 0.01 | -0.06 | -0.02 | -0.19 | 0.21 | 0.05 | 0.36 | -0.01 |
| IFN- α | 3.3±1.0 | 0.11 | 0.04 | 0.16 | 0.19 | -0.09 | 0.21 | -0.02 | 0.10 |
| IL-23 | 413±166 | 0.07 | -0.29 | -0.19 | -0.28 | -0.18 | -0.25 | -0.09 | -0.26 |

Boldface letters mean statistically significant. * $P < 0.05$.



Matsuda KM et al.
Figure 1



Matsuda KM et al.
Figure 2